Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients

Marta Scorsetti, Filippo Alongi, Andrea Riccardo Filippi, Sara Pentimalli, Pierina Navarria, Elena Clerici, Simona Castiglioni, Angelo Tozzi, Giacomo Reggiori, Pietro Mancosu, Umberto Ricardi

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aims and background. To describe feasibility, tolerability and clinical outcomes of stereotactic body radiation therapy (SBRT) in the treatment of adrenal metastases in 34 consecutive cancer patients. Material and methods. Between March 2004 and July 2010, a total of 34 consecutive patients, accounting for 36 adrenal metastatic lesions, were treated with SBRT. SBRT treatments were delivered by a Linac Varian 600 with microMLC (3DLine, Elekta, Stockholm, Sweden) and a Linac ELEKTA Precise (Elekta). All 34 patients were clinically and radiologically evaluated during and after completion of SBRT. Following outcomes were taken into account: best clinical response at any time, local control, time to systemic progression, time to local progression, overall survival and toxicity. Survival was estimated by the Kaplan-Meier method and factor potentially affecting outcomes were analyzed with Cox regression analysis. Results. Total RT doses ranged from 20 Gy in 4 fractions to 45 Gy in 18 fractions (median dose: 32 Gy; median number of fractions: 4). All doses were prescribed to the 95% isodose line. No cases of Grade ≥ 3 toxicity were recorded. At a median follow-up time of 41 months (range, 1275) 22 patients were alive. Three of 28 lesions (11%) showed complete response, 13/28 (46%) partial response, 10/28 (36%) stable disease and 2/28 (7%) progressed in the treated area. Local failure was observed in 13 cases. Actuarial local control rates at one and two years were 66% and 32%, respectively. Median time to local progression was 19 months. Median survival was 22 months. Conclusion. SBRT in adrenal gland metastasis is feasible without significant acute and late toxicities, with a good rate of local control. New SBRT fractionation schemes and the possibility to combine new systemic approaches should be investigated in order to further increase local control and reduce systemic disease progression.

Original languageEnglish
Pages (from-to)618-623
Number of pages6
JournalActa Oncologica
Volume51
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Radiosurgery
Adrenal Glands
Radiotherapy
Neoplasm Metastasis
Survival
Sweden
Disease Progression
Regression Analysis
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases : A retrospective analysis of 34 patients. / Scorsetti, Marta; Alongi, Filippo; Filippi, Andrea Riccardo; Pentimalli, Sara; Navarria, Pierina; Clerici, Elena; Castiglioni, Simona; Tozzi, Angelo; Reggiori, Giacomo; Mancosu, Pietro; Ricardi, Umberto.

In: Acta Oncologica, Vol. 51, No. 5, 05.2012, p. 618-623.

Research output: Contribution to journalArticle

@article{8ef258ded0b24ac5aa1f4c3f584f6c7f,
title = "Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients",
abstract = "Aims and background. To describe feasibility, tolerability and clinical outcomes of stereotactic body radiation therapy (SBRT) in the treatment of adrenal metastases in 34 consecutive cancer patients. Material and methods. Between March 2004 and July 2010, a total of 34 consecutive patients, accounting for 36 adrenal metastatic lesions, were treated with SBRT. SBRT treatments were delivered by a Linac Varian 600 with microMLC (3DLine, Elekta, Stockholm, Sweden) and a Linac ELEKTA Precise (Elekta). All 34 patients were clinically and radiologically evaluated during and after completion of SBRT. Following outcomes were taken into account: best clinical response at any time, local control, time to systemic progression, time to local progression, overall survival and toxicity. Survival was estimated by the Kaplan-Meier method and factor potentially affecting outcomes were analyzed with Cox regression analysis. Results. Total RT doses ranged from 20 Gy in 4 fractions to 45 Gy in 18 fractions (median dose: 32 Gy; median number of fractions: 4). All doses were prescribed to the 95{\%} isodose line. No cases of Grade ≥ 3 toxicity were recorded. At a median follow-up time of 41 months (range, 1275) 22 patients were alive. Three of 28 lesions (11{\%}) showed complete response, 13/28 (46{\%}) partial response, 10/28 (36{\%}) stable disease and 2/28 (7{\%}) progressed in the treated area. Local failure was observed in 13 cases. Actuarial local control rates at one and two years were 66{\%} and 32{\%}, respectively. Median time to local progression was 19 months. Median survival was 22 months. Conclusion. SBRT in adrenal gland metastasis is feasible without significant acute and late toxicities, with a good rate of local control. New SBRT fractionation schemes and the possibility to combine new systemic approaches should be investigated in order to further increase local control and reduce systemic disease progression.",
author = "Marta Scorsetti and Filippo Alongi and Filippi, {Andrea Riccardo} and Sara Pentimalli and Pierina Navarria and Elena Clerici and Simona Castiglioni and Angelo Tozzi and Giacomo Reggiori and Pietro Mancosu and Umberto Ricardi",
year = "2012",
month = "5",
doi = "10.3109/0284186X.2011.652738",
language = "English",
volume = "51",
pages = "618--623",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases

T2 - A retrospective analysis of 34 patients

AU - Scorsetti, Marta

AU - Alongi, Filippo

AU - Filippi, Andrea Riccardo

AU - Pentimalli, Sara

AU - Navarria, Pierina

AU - Clerici, Elena

AU - Castiglioni, Simona

AU - Tozzi, Angelo

AU - Reggiori, Giacomo

AU - Mancosu, Pietro

AU - Ricardi, Umberto

PY - 2012/5

Y1 - 2012/5

N2 - Aims and background. To describe feasibility, tolerability and clinical outcomes of stereotactic body radiation therapy (SBRT) in the treatment of adrenal metastases in 34 consecutive cancer patients. Material and methods. Between March 2004 and July 2010, a total of 34 consecutive patients, accounting for 36 adrenal metastatic lesions, were treated with SBRT. SBRT treatments were delivered by a Linac Varian 600 with microMLC (3DLine, Elekta, Stockholm, Sweden) and a Linac ELEKTA Precise (Elekta). All 34 patients were clinically and radiologically evaluated during and after completion of SBRT. Following outcomes were taken into account: best clinical response at any time, local control, time to systemic progression, time to local progression, overall survival and toxicity. Survival was estimated by the Kaplan-Meier method and factor potentially affecting outcomes were analyzed with Cox regression analysis. Results. Total RT doses ranged from 20 Gy in 4 fractions to 45 Gy in 18 fractions (median dose: 32 Gy; median number of fractions: 4). All doses were prescribed to the 95% isodose line. No cases of Grade ≥ 3 toxicity were recorded. At a median follow-up time of 41 months (range, 1275) 22 patients were alive. Three of 28 lesions (11%) showed complete response, 13/28 (46%) partial response, 10/28 (36%) stable disease and 2/28 (7%) progressed in the treated area. Local failure was observed in 13 cases. Actuarial local control rates at one and two years were 66% and 32%, respectively. Median time to local progression was 19 months. Median survival was 22 months. Conclusion. SBRT in adrenal gland metastasis is feasible without significant acute and late toxicities, with a good rate of local control. New SBRT fractionation schemes and the possibility to combine new systemic approaches should be investigated in order to further increase local control and reduce systemic disease progression.

AB - Aims and background. To describe feasibility, tolerability and clinical outcomes of stereotactic body radiation therapy (SBRT) in the treatment of adrenal metastases in 34 consecutive cancer patients. Material and methods. Between March 2004 and July 2010, a total of 34 consecutive patients, accounting for 36 adrenal metastatic lesions, were treated with SBRT. SBRT treatments were delivered by a Linac Varian 600 with microMLC (3DLine, Elekta, Stockholm, Sweden) and a Linac ELEKTA Precise (Elekta). All 34 patients were clinically and radiologically evaluated during and after completion of SBRT. Following outcomes were taken into account: best clinical response at any time, local control, time to systemic progression, time to local progression, overall survival and toxicity. Survival was estimated by the Kaplan-Meier method and factor potentially affecting outcomes were analyzed with Cox regression analysis. Results. Total RT doses ranged from 20 Gy in 4 fractions to 45 Gy in 18 fractions (median dose: 32 Gy; median number of fractions: 4). All doses were prescribed to the 95% isodose line. No cases of Grade ≥ 3 toxicity were recorded. At a median follow-up time of 41 months (range, 1275) 22 patients were alive. Three of 28 lesions (11%) showed complete response, 13/28 (46%) partial response, 10/28 (36%) stable disease and 2/28 (7%) progressed in the treated area. Local failure was observed in 13 cases. Actuarial local control rates at one and two years were 66% and 32%, respectively. Median time to local progression was 19 months. Median survival was 22 months. Conclusion. SBRT in adrenal gland metastasis is feasible without significant acute and late toxicities, with a good rate of local control. New SBRT fractionation schemes and the possibility to combine new systemic approaches should be investigated in order to further increase local control and reduce systemic disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84862073286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862073286&partnerID=8YFLogxK

U2 - 10.3109/0284186X.2011.652738

DO - 10.3109/0284186X.2011.652738

M3 - Article

C2 - 22263925

AN - SCOPUS:84862073286

VL - 51

SP - 618

EP - 623

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 5

ER -